Trial Profile
Phase 2 Evaluation of the Vitagen Extracorporeal Liver Assist Device (ELAD) System in the Management of the Patients With Fulminant Hepatic Failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2013
Price :
$35
*
At a glance
- Drugs Extracorporeal hepatocyte-based therapy (Primary)
- Indications Liver failure
- Focus Therapeutic Use
- Sponsors Vital Therapies
- 07 Dec 2013 New trial record